9 October 2025
Since its launch in 2017 with just 20 molecules, our Molecules to order program has steadily expanded with one goal in mind: to make high-quality, well-characterized preclinical molecules freely available to the global scientific community. Today, we mark a major milestone – 100 molecules now available through our opnMe platform.
What began with a small collection of molecules has grown into a powerful open science resource spanning more than 10,000 orders from researchers in more than 54 countries. Along the way, these molecules have contributed to over 240 scientific publications, advancing discoveries across various research fields.
Hear what researchers are saying about opnMe molecules:
“opnMe is an excellent resource. Ordering is straightforward, and the delivery is consistently quick and reliable. We look forward to continuing to work with their compounds.” Dr. Martin Steger, Head of Degrader Biochemistry, NEOsphere Biotechnologies GmbH
"I had an excellent experience working with opnMe. Their customer service team was friendly, responsive, and answered my questions promptly. I truly appreciate their efficiency and support in facilitating our drug screening work.” Zhicheng Duo, Associate Professor, Clemson University, US
“opnMe is in a way democratizing access to tool compounds. Boehringer Ingelheim should be commended on this absolutely incredibly important initiative.” Alessio Ciulli, Professor, University of Dundee
This milestone reflects the growing reach and impact of the program as it continues to support independent research and foster collaboration across the scientific community.
“opnMe accelerates research across the globe by sharing our high-quality probe molecules — validated by enthusiastic feedback from the scientific community.” Jürgen Mack, Vice President Global Medicinal Chemistry at Boehringer Ingelheim
Explore the best-seller molecules in the table or the full collection of 100 molecules below.
| Molecule class | Best-seller molecules |
| Enzymes | FAS inhibitor |
| Epigenetic targets | SMARCA2/4 PROTAC (ACBI1) | BET PROTAC (MZ1) | BRD7/BRD9 PROTAC (VZ185) |
| GPCRs | β2AR agonist |
| Ion channels | NHE1 inhibitor |
| Kinases | CDK8 inhibitor | Aurora B inhibitor | SYK inhibitor |
| Membrane proteins | MLKL inhibitor |
| Membrane transporters | LOX1 inhibitor |
| Nuclear receptors | GR agonist |
| PPIs | KRAS inhibitor | BCL-6 degrader | BCL-6 inhibitor |
| RNA targets | TPP RIBOSWITCH activator |
No registration required
Subscribe to our newsletter to stay updated as we add new molecules to opnMe.com.
About opnMe:
opnMe.com, the open innovation portal of Boehringer Ingelheim, fosters science and collaboration initiatives in areas of high unmet medical need. As part of our first pillar, the “Molecules to Order”, we share well-characterized tool compounds free of charge with no IP strings attached. With our “opn2EXPERTS” and “techMATCH” programs, we enlist scientific advice on key biologic issues to fuel further drug discovery and deliver novel solutions that benefit unmet patient needs. Our opn2TALENTS PostDoc grants, provide an opportunity for high-caliber talents to pitch their scientific approaches for well-defined research questions to conduct their research at one of our discovery research sites.